Live Earnings Conference Call: Verrica Pharmaceuticals will host a live Q3 2026 earnings call on November 12, 2026 at 4:30PM ET. Follow this link to get details and listen to Verrica Pharmaceuticals' Q3 2026 earnings call when it goes live. Get details. NASDAQ:VRCA Verrica Pharmaceuticals (VRCA) Stock Price, News & Analysis $3.97 +0.06 (+1.43%) As of 02:56 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Verrica Pharmaceuticals Stock (NASDAQ:VRCA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get VRCA alerts:Sign Up Key Stats Today's Range$3.83▼$4.2150-Day Range$3.09▼$5.3952-Week Range$3.08▼$9.82Volume80,544 shsAverage Volume86,611 shsMarket Capitalization$68.14 millionP/E RatioN/ADividend YieldN/APrice Target$12.67Consensus RatingHold Company Overview Verrica Pharmaceuticals Inc. is a dermatology-focused biopharmaceutical company developing and commercializing therapies for skin diseases that have limited or inadequate treatment options. The company’s activities center on prescription products designed for use by dermatologists and other healthcare professionals. Verrica’s lead commercial product is YCANTHE (cantharidin) topical solution, 0.7%, a prescription treatment approved by the U.S. Food and Drug Administration for molluscum contagiosum in adults and children two years of age and older. The product is applied in a healthcare setting and is intended to help treat the viral skin lesions associated with the condition. The company has also pursued additional dermatology indications for its cantharidin-based product candidate, including common warts, as well as other investigational treatments for skin diseases. Verrica was founded in 2018 and is headquartered in West Chester, Pennsylvania. Its commercial operations have primarily focused on the United States, where YCANTHE is marketed through dermatology and healthcare channels.AI Generated. May Contain Errors. Read More Verrica Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreVRCA MarketRank™: 3.480276907 of 5 starsVerrica Pharmaceuticals scored higher than 70% of companies evaluated by MarketBeat, and ranked 224th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingVerrica Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialVerrica Pharmaceuticals has a consensus price target of $12.67, representing about 219.4% upside from its current price of $3.97.Amount of Analyst CoverageVerrica Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Verrica Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Verrica Pharmaceuticals are expected to grow in the coming year, from ($1.90) to ($1.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verrica Pharmaceuticals is -2.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verrica Pharmaceuticals is -2.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerrica Pharmaceuticals has a P/B Ratio of 2.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Verrica Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.02% of the float of Verrica Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVerrica Pharmaceuticals has a short interest ratio ("days to cover") of 4.58.Change versus previous monthShort interest in Verrica Pharmaceuticals has recently increased by 26.89%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVerrica Pharmaceuticals does not currently pay a dividend.Dividend GrowthVerrica Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.43 News SentimentVerrica Pharmaceuticals has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Verrica Pharmaceuticals this week, compared to 2 articles on an average week. Company Ownership4.8 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of Verrica Pharmaceuticals in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $55,160.00 in company stock, which represents 0.0810% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Verrica Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $55,160.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders52.90% of the stock of Verrica Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.45% of the stock of Verrica Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Verrica Pharmaceuticals' insider trading history. Receive VRCA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verrica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VRCA Stock News HeadlinesVerrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in LondonNovember 10 at 12:28 PM | finance.yahoo.comVerrica Pharmaceuticals (NASDAQ:VRCA) Downgraded by Wall Street Zen to "Strong Sell"November 7, 2026 | americanbankingnews.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 12 at 1:00 AM | Weiss Ratings (Ad)Verrica Pharmaceuticals (VRCA) Set to Post Quarterly Earnings on FridayNovember 6, 2026 | americanbankingnews.comVerrica Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026November 5, 2026 | globenewswire.comVerrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit FacilityOctober 22, 2026 | globenewswire.comLake Street Keeps Their Buy Rating on Verrica Pharmaceuticals (VRCA)October 6, 2026 | theglobeandmail.comVerrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology ConferencesSeptember 30, 2026 | globenewswire.comSee More Headlines VRCA Stock Analysis - Frequently Asked Questions How have VRCA shares performed this year? Verrica Pharmaceuticals' stock was trading at $8.31 at the start of the year. Since then, VRCA shares have decreased by 52.3% and is now trading at $3.9660. How were Verrica Pharmaceuticals' earnings last quarter? Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) announced its earnings results on Tuesday, May, 12th. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.18. The firm earned $5.02 million during the quarter, compared to analysts' expectations of $4.51 million. Verrica Pharmaceuticals had a negative net margin of 102.84% and a negative trailing twelve-month return on equity of 407.11%. Read the conference call transcript. When did Verrica Pharmaceuticals' stock split? Verrica Pharmaceuticals's stock reverse split before market open on Friday, July 25th 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 24th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Verrica Pharmaceuticals IPO? Verrica Pharmaceuticals (VRCA) raised $75 million in an IPO on Friday, June 15th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen acted as the underwriters for the IPO. Who are Verrica Pharmaceuticals' major shareholders? Top institutional shareholders of Verrica Pharmaceuticals include State Street Corp (0.17%) and Fifth Third Bancorp (0.16%). Insiders that own company stock include Paul B Manning, Perceptive Advisors Llc, Jayson Rieger, Ted White, David Zawitz, Christopher G Hayes, Joe Bonaccorso, John J Kirby and Noah L Rosenberg. View institutional ownership trends. How do I buy shares of Verrica Pharmaceuticals? Shares of VRCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Verrica Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Verrica Pharmaceuticals investors own include Iovance Biotherapeutics (IOVA), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Rithm Capital (RITM), Energy Transfer (ET) and NIO (NIO). Company Calendar Today11/12/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 VRCA's financial health is in the Yellow zone, according to TradeSmith. VRCA has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:VRCA CIK1660334 Webwww.verrica.com Phone(484) 453-3300FaxN/AEmployees76Year Founded2013Price Target and Rating Average Price Target for Verrica Pharmaceuticals$12.67 High Price Target$17.00 Low Price Target$9.00 Potential Upside/Downside+226.0%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$17.89 million Net Margins-102.84% Pretax Margin-102.84% Return on Equity-407.11% Return on Assets-70.17% Debt Debt-to-Equity Ratio0.18 Current Ratio1.45 Quick Ratio1.33 Sales & Book Value Annual Sales$35.58 million Price / Sales1.88 Cash FlowN/A Price / Cash FlowN/A Book Value$1.55 per share Price / Book2.51Miscellaneous Outstanding Shares17,180,000Free Float8,091,000Market Cap$66.74 million OptionableOptionable Beta1.69 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:VRCA) was last updated on 11/12/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSocial Security’s trust fund runs short in 2032. Guess who controls Congress.Social Security's retirement trust fund is projected to run dry in late 2032, per the 2026 Trustees Report. Af...Priority Gold | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verrica Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verrica Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
